cognitive cybersecurity intelligence

News and Analysis

Search

Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking

Insulin spending topped $22bn in 2022 and its costs have tripled in the last decade, with major producers following last year’s Inflation Reduction Act and setting a $35 cap on out-of-pocket expenditure. Despite big three firms dominating the market with cheaper versions of branded products, new alternatives are emerging, such as Civica Rx, a nonprofit planning $30 per-vial insulin by 2024, and the state-run CalRx scheme that’s focusing first on insulin.

Source: medcitynews.com –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

How to Root Out Malicious Employees

Insider threats pose one of the largest security risks to organizations, and often go unnoticed or unaddressed. Malicious and negligent employees can commit devastating acts,